Pyrazole: A Promising Agent for The Ovarian and Prostate Cancer Therapy

Pyrazole-based derivatives have become an important chemo-type in modern anticancer drug discovery because of their ability to modulate key molecular pathways involved in tumor initiation and progression. Darolutamide, a nonsteroidal anti-androgen, and niraparib, a selective PARP inhibitor, are prominent clinically validated examples demonstrating the therapeutic relevance of the pyrazole scaffold. [1–5]In darolutamide, the pyrazole core serves as a crucial pharmacophoric element that facilitates noncompetitive interaction with the androgen receptor (AR). Its distinct structural features enable high-affinity binding, inhibit AR nuclear translocation, and overcome resistance commonly associated with first- and second-generation AR antagonists. This structural robustness underlies its marked efficacy, in patients with metastatic(non) castration resistant prostate cancer. Mechanistically, darolutamide selectively antagonizes AR signaling, thereby suppressing androgen-driven proliferation of prostate cancer cells.In niraparib, the pyrazole ring plays a pivotal role in achieving potent and selective inhibition of poly(ADP-ribose) polymerase (PARP) enzymes. This strategy exploits synthetic lethality in tumors exhibiting defects in homologous recombination repair (HRR). The nitrogen atoms of the pyrazole ring and their electronic characteristics are essential for productive binding within the PARP catalytic site. PARP inhibition by Niraparib leads to the cluster of unrepaired DNA impairment in HRR-deficient tumor cells. Clinically, this mechanism has produced significant benefits in ovarian cancers with BRCA mutations and, when it combined with abiraterone acetate, it improves the outcomes in metastatic castration-resistant prostate cancer.Overall, pyrazole-containing agents such as darolutamide and niraparib exemplify rational, target-directed therapeutic design. Their integration into treatment regimens highlights the value of pathway-specific modulation, and continued clinical investigation is warranted to optimize combinations and improve patient outcomes.